With a short percentage of outstanding shares of 0.43%, Ainos, Inc. (NASDAQ:AIMD) is among the 7 Best Machine Learning Stocks to Buy According to Short Sellers.
Ainos, Inc. (NASDAQ:AIMD) announced on April 17 that it continues to expand deployments of its Smell AI platform, powered by AI Nose technology, across semiconductor, robotics, and healthcare infrastructure markets. The expansion was highlighted in third-party research published by VASRO, which described Smell AI’s transition from isolated sensing applications into a scalable, multi-domain AI perception platform. The report identified 2026 as a potentially important commercialization year as Ainos advances toward broader deployment and recurring revenue generation. As part of the initiative, the company has begun implementing Smell AI within hospital infrastructure through partnerships with MacKay Memorial Hospital and Topco Scientific Co., Ltd. Initial applications are focused on environmental monitoring and operational safety across HVAC systems, power infrastructure, chemical handling environments, clinical laboratories, and MRI facilities. According to the report, the technology serves as an early-detection perception layer capable of identifying otherwise invisible environmental risks, including chemical exposure and airborne contaminants.
Earlier, on April 8, Ainos, Inc. (NASDAQ:AIMD) announced a strategic partnership with MacKay Memorial Hospital and Topco Scientific to deploy its AI Nose technology throughout high-risk hospital environments. The collaboration represents a significant step in extending the company’s Smell AI platform beyond industrial and environmental safety applications and into healthcare infrastructure. The initial rollout, which began in April 2026, is focused on four critical operational areas within hospital facilities where environmental monitoring and safety optimization are particularly important.
Ainos, Inc. (NASDAQ:AIMD) is a diversified medical technology and artificial intelligence company specializing in digital olfaction, or “smelltech,” as well as immune therapeutics. Headquartered in Houston and founded in 1984, the company develops AI-driven scent intelligence technologies designed to help machines detect illnesses, environmental hazards, and industrial changes through advanced olfactory data analysis. Its proprietary Smell AI platform converts scent signals into structured machine-readable data to support healthcare, industrial, and infrastructure applications.
The company’s growing partnerships in healthcare infrastructure and increasing validation from third-party research could position Ainos to capitalize on the rising demand for AI-enabled environmental monitoring and predictive safety systems.
While we acknowledge the risk and potential of AIMD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AIMD and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 8 Best Energy Infrastructure Stocks That Will Skyrocket and 10 Tech Stocks That Could Make You a Millionaire.
Disclosure: None. Follow Insider Monkey on Google News.
